Company
Headquarters: Shenzhen, China
Employees: 811
CEO: Dr. Xian-Ping Lu
CN¥6.85 Billion
CNY as of July 1, 2024
US$942.6 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines that are in various research phase of the specific global intellectual property protection in three areas, such as cancer, metabolic diseases, and autoimmune diseases. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is based in Shenzhen, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Shenzhen Chipscreen Biosciences Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688321 wb_incandescent